• Теги
    • избранные теги
    • Компании1826
      • Показать ещё
      • Показать ещё
      Международные организации72
      • Показать ещё
      Страны / Регионы703
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
15 сентября, 13:52

Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.

14 сентября, 18:25

Glaxo's Shingles Candidate Gets Positive FDA Committee Vote

Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.

Выбор редакции
28 августа, 21:32

Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline

In need of fresh ideas, the drugmaker is banking on implantable devices capable of altering electrical impulses in the bodyBritain’s biggest drugmaker, GlaxoSmithKline, under pressure to improve its development pipeline and financial performance, is pinning its hopes on a radical new approach: “electroceuticals”. Also called bioelectronics, the idea is that tiny electronic implants will be able to treat a vast range of chronic diseases, such as diabetes, asthma, chronic obstructive pulmonary disease (COPD), arthritis, hypertension and other heart conditions, and gastrointestinal diseases. Continue reading...

30 июня, 17:46

Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

29 июня, 16:54

Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion

Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.

28 июня, 16:26

Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

27 июня, 20:53

Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike

Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike

26 июня, 16:00

Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

22 июня, 17:06

Glaxo's (GSK) Shingles Candidate Phase III Data Positive

GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

22 июня, 16:47

Novartis Announces Positive Results for Cardiovascular Drug

Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

22 июня, 00:18

U.S. Supreme Court Ruling Threatens Massive Talc Litigation Against J&J

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer. New Jersey-based J&J has been battling a series of lawsuits over its talc-based products, including Johnson’s Baby Powder, brought by around 5,950 women and their families. The company denies any link between talc and cancer. A fifth of the plaintiffs have cases pending in state court in St. Louis, where juries in four trials have hit J&J and a talc supplier with $307 million in verdicts. Those four cases and most of the others on the St. Louis docket involve out-of-state plaintiffs suing an out-of-state company. On Monday, the Supreme Court ruled 8-1 in a case involving Bristol-Myers Squibb Co that state courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there. The ruling immediately led a St. Louis judge at J&J’s urging to declare a mistrial in the latest talc case, in which two of the three women at issue were from out of state. It also could imperil prior verdicts and cases that have yet to go to trial. “We believe the recent U.S. Supreme Court ruling on the Bristol-Myers Squibb matter requires reversal of the talc cases that are currently under appeal in St. Louis,” J&J said in a statement. The question of where such lawsuits can be filed has been the subject of fierce debate. The business community has argued plaintiffs should not be allowed to shop around for the most favorable court to bring lawsuits, while injured parties claim corporations are trying to deny them access to justice. Along with talc cases, large-scale litigation alleging injuries from Bayer AG’s Essure birth control device in Missouri and California and GlaxoSmithKline’s antidepressant Paxil in California and Illinois are examples of other cases where defendants could utilize the Supreme Court decision. Although he declared a mistrial on Monday, St. Louis Circuit Judge Rex Burlison left the door open for the plaintiffs to argue they still have jurisdiction. Plaintiffs lawyer Ted Meadows said he would argue the St. Louis court still had jurisdiction based on a Missouri-based bottler J&J used to package its talc products, which he said would create a sufficient connection to the state. “It’s very disappointing to mistry a case because the Supreme Court changed the rules on us,” said Meadows. The lawsuit decided by the high court on Monday involved claims against Bristol-Myers and California-based drug distributor McKesson Corp by 86 California residents and 575 non-Californians over the blood thinner Plavix. Beyond Monday’s mistrial, the Supreme Court’s ruling could bolster a pending appeal by J&J of a $72 million verdict in favor of the family of Alabama resident Jacqueline Fox, who died in 2015. A Missouri appeals court had said in May it would wait until the Supreme Court issued its decision to decide the appeal. J&J has won only one of the five trials so far in Missouri. It previously sought to move talc cases out of St. Louis, but the Missouri Supreme Court in January denied its bid. The company has also cast the St. Louis court as overly plaintiff-friendly and has allowed evidence linking talc to cancer that was rejected by a New Jersey state court judge overseeing over 200 talc cases. The plaintiffs are appealing. The talc verdicts against J&J led the business-friendly American Tort Reform Association last year to declare the St. Louis state court the nation’s top “Judicial Hellhole.” Now J&J could try to use the Supreme Court ruling to dismiss many of the cases it faces in Missouri, according to legal experts. Corporations facing a large volume of cases in venues chosen by plaintiffs will likely cite the Supreme Court to try to dismiss those claims, said Rusty Perdew, a defense lawyer at the law firm Locke Lord. “You have a bunch of defendants who can go back and say, ‘Judge, you got that wrong and you’re going to have to dismiss claims by all those plaintiffs,’” he said. (This story was corrected to show that Perdew was speaking about corporations in general, not J&J, in next-to-last paragraph.)   (Reporting by Nate Raymond in Boston; Editing by Tom Brown and Bill Trott) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

19 июня, 23:56

Novartis (NVS) Biosimilar of MabThera Approved in the EU

Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.

Выбор редакции
19 июня, 19:26

GSK's new pharma head to join in September after AstraZeneca tussle

GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca. Britain's biggest drugmaker poached Miels in January in the first major appointment by incoming GSK Chief Executive Emma Walmsley. GSK said on Monday it had now struck an agreement with AstraZeneca for Miels to start on Sept. 4, avoiding the need for a court case over his contract.

19 июня, 17:21

GlaxoSmithKline's Benlysta Positive in Continuation Trial

GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).

16 июня, 16:45

Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?

Let's put GlaxoSmithKline PLC (GSK) stock into this equation and find out if it is a good choice for value-oriented investors right now.

16 июня, 00:24

Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

14 июня, 00:16

Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen

Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.

Выбор редакции
13 июня, 10:41

Epizyme (EPZM) Down 19.2% Since Earnings Report: Can It Rebound?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

13 июня, 00:02

Novartis Presents Positive Data on CAR-T Cell Therapy Drug

Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate.

09 июня, 15:46

Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises

Inovio Pharmaceuticals, Inc (INO) initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human papillomavirus.